BARDA Selects Edesa Biotech's Paridiprubart For U.S. Funded Platform Trial In General ARDS

• This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes.
• This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS.
• Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates.

TORONTO, ON / ACCESSWIRE / June 24, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, announced today that its first-in-class drug candidate has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study.